Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

PTN

Palatin Technologies (PTN)

Palatin Technologies Inc New
から:
次の項目別のソート:
 Showing the most relevant articles for your search:AMEX:PTN
日付受信時刻ニュースソース見出しコード企業名
2024/07/1800 : 14Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]AMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/07/1705 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/06/2121 : 00PR Newswire (US)Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsAMEX:PTNPalatin Technologies Inc New
2024/06/2020 : 30PR Newswire (US)Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)AMEX:PTNPalatin Technologies Inc New
2024/06/1220 : 30PR Newswire (US)Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
2024/05/1521 : 40Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
2024/05/1521 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:PTNPalatin Technologies Inc New
2024/05/1520 : 30PR Newswire (US)Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAMEX:PTNPalatin Technologies Inc New
2024/05/0920 : 30PR Newswire (US)Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024AMEX:PTNPalatin Technologies Inc New
2024/05/0220 : 30PR Newswire (US)Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
2024/04/3020 : 30PR Newswire (US)Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024AMEX:PTNPalatin Technologies Inc New
2024/04/0820 : 30PR Newswire (US)Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024AMEX:PTNPalatin Technologies Inc New
2024/03/0807 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
2024/03/0502 : 57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesAMEX:PTNPalatin Technologies Inc New
2024/02/2821 : 30PR Newswire (US)Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)AMEX:PTNPalatin Technologies Inc New
2024/02/1523 : 00Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
2024/02/1521 : 30PR Newswire (US)Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAMEX:PTNPalatin Technologies Inc New
2024/02/1506 : 17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:PTNPalatin Technologies Inc New
2024/02/1504 : 55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:PTNPalatin Technologies Inc New
2024/02/0921 : 30PR Newswire (US)Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024AMEX:PTNPalatin Technologies Inc New
2024/02/0521 : 30PR Newswire (US)Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)AMEX:PTNPalatin Technologies Inc New
2024/02/0207 : 16Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
2024/02/0206 : 00PR Newswire (US)Palatin Announces Closing of $10 Million Registered Direct OfferingAMEX:PTNPalatin Technologies Inc New
 Showing the most relevant articles for your search:AMEX:PTN